- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Clinical Trials
- January 2020
- 269 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Drug Pipelines
- September 2020
- 121 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- May 2023
- 89 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- May 2022
- 115 Pages
Global
From €1922EUR$2,000USD£1,643GBP
The Mild Cognitive Impairment Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat mild cognitive impairment, a condition characterized by a decline in cognitive abilities that is not severe enough to be classified as dementia. These drugs are typically used to improve memory, concentration, and other cognitive functions. Commonly prescribed drugs include cholinesterase inhibitors, memantine, and other psychostimulants.
The Mild Cognitive Impairment Drug market is highly competitive, with many companies offering similar products. Some of the major players in the market include Pfizer, Novartis, Merck, Johnson & Johnson, and Eli Lilly. Other companies include Allergan, AstraZeneca, and Sunovion. Show Less Read more
